Rare Disease Trials: To Placebo or Not to Placebo?

Time: 11:00 am
day: Clinical - AM

Details:

• Key considerations when considering incorporating a placebo control
• Outlining the implications to the sponsor, regulators, and patients
• When is a placebo considered unethical or unfeasible?
• How are global regulators’ attitudes on placebo control arms evolving?

Speakers:

Mitra Tavakkoli Executive physician scientist with extensive rare disease gene therapy drug development experience